Fc-Silenced Antibody Expression Service

Achieve zero immune activation – with our expression service for truly Fc-silenced antibodies.

At evitria, we can express truly Fc-silenced antibodies at highest quality, thanks to STR technology and our CHO cell expression platform.

We understand the critical importance of eliminating unwanted immune system activation in several research and therapeutic applications.

Through our partnership with mAbsolve, we utilize the innovative STR technology – a unique combination of three mutations in the Fc domain – that completely silences Fc gamma receptor interactions. This results in antibodies with zero activity above background noise, surpassing most of the previous efforts in Fc engineering.

LET’S GET IN TOUCH

0%

Fc activity

99%

projects successfully completed on time

20.000 +

antibodies purified overall for customers worldwide

4 weeks

from antibody sequence to delivery

Reliably Fc-silenced – mandatory for patient safety

For anti-viral antibodies, anti-inflammatory antibodies, and other therapeutic approaches using neutralizing antibodies, using Fc-silenced antibodies is essential to avoid unintended immune system activation that can interfere with therapeutic efficacy.

Therefore, our Fc-silenced antibodies completely and reliably eliminate immune effector functions mediated by the Fc region, such as binding to Fc gamma receptors on immune cells. This prevents side effects like cytokine release and antibody-dependent cell-mediated cytotoxicity (ADCC), maintaing precise antigen binding without triggering immune responses.

LET’S TALK ABOUT YOUR PROJECT

What makes evitria’s STR-modified Fc-silenced antibody production service stand out

evitria’s STR-modified Fc-silenced antibody production service offers unparalleled efficacy in completely eliminating Fc effector functions. Here’s what you can expect from us:

1. True Fc silencing with STR technology – Our antibodies incorporate mAbsolve’s STR mutations in the CH2 domain of the Fc region, achieving true Fc silencing with no residual activity. This is critical for antibody therapeutics where even minimal immune activity may pose a danger to patients.

2. Reduced side effects – By preventing binding to Fcγ receptors on immune cells like macrophages, B-cells, T-cells, and natural killer cells, our antibodies avoid triggering ADCC and cytokine release. This reduces potential side effects in therapeutic applications.

3. Recombinant production in CHO cells – We utilize recombinant antibody production in Chinese Hamster Ovary (CHO) cell lines, known for their reliability and high-quality protein expression. This ensures consistent glycosylation patterns and proper folding, essential for antibody stability and function.

4. Fast turnaround time – With our efficient workflow, we deliver antibodies from sequence to purified product in just 4 weeks. This rapid production cycle accelerates your research and development timelines.

5. Expertise in antibody engineering – Our team has extensive experience in antibody engineering, including Fc region modifications, to tailor antibodies to your specific needs. Whether you require human IgGs like human IgG1, murine IgGs like mouse IgG2a, or other species and isotypes, we can accommodate your requirements.

6. Comprehensive support – We offer technical support throughout your project, including assistance with experimental design, receptor binding assays, and interpretation of results.

7. Freedom to operate – Our partnership with mAbsolve ensures that you have the necessary licences for preclinical use, providing a clear commercialization pathway without intellectual property constraints.
By choosing evitria, you benefit from cutting-edge Fc silencing technology, reliable production methods, and a team dedicated to supporting your success in the lab and beyond.

GET IN CONTACT

Unsure on what Fc-silenced antibody you should use?

We’ve got you covered! Regardless of where your research is taking you, Dr. Desmond Schofield is dedicated to supporting you.

Dr. Desmond Schofield
Chief Business Officer at evitria

ds@evitria.com

Expression service for truly Fc-silenced antibodies – and beyond

Beyond Fc-silenced antibodies, evitria offers a range of recombinant antibody production services. These include:

Recombinant monoclonal antibody production service
Afucosylated antibody production service
Bispecific antibody production service
Expression services for other proteins

Our expertise in pharmacokinetics, immunogenicity optimization, and Fc engineering allows us to customize antibodies for various applications. With our CHO cell expression platform, we ensure high-quality, scalable production to meet your project’s demands.

GET A QUOTE

From sequence to antibody in 4 weeks

We know how tight timelines in biotechnological projects can be. With resources and know-how at hand, our efficient workflow allows us to provide you with Fc-silenced antibodies within only 4 weeks. Starting with molecular biology, large-scale expression commences after 2 weeks, followed by purification, extensive analytics, and – finally – shipment to our customers worldwide.

WEEK 1

WEEK 2

WEEK 3

WEEK 4

Pilot Study*

Larger-scale expression

Purification

Finaly analytics

Shipment

FAQs on our Fc-silenced antibody expression service

How do you ensure entirely Fc-silenced antibodies?

At evitria, we ensure entirely Fc-silenced antibodies by utilizing mAbsolve’s STR technology, which involves specific amino acid substitutions in the Fc region of antibodies like human IgG1 and other variants. These substitutions, eliminate binding to Fc gamma receptors (FcγRs) such as FcγRI and FcγRIIIA. By engineering the Fc domain, we remove Fc-mediated effector functions like antibody-dependent cellular cytotoxicity (ADCC) and cytokine release. Our recombinant monoclonal antibodies (mAbs) are produced in CHO cell lines and undergo rigorous characterization to confirm their suitability for both in vitro and in vivo experiments.

What is the principle behind mAbsolve’s STR technology?

mAbsolve’s STR technology is based on engineering of the antibody’s Fc region to disrupt interactions with Fc gamma receptors. By introducing specific amino acid substitutions at key residues in the Fc domain, the technology prevents binding to FcγRs without affecting the Fab region’s ability to bind to epitopes on target antigens. This principle can be used to create Fc fusion proteins and chimeric antibodies that are Fc-silenced. The STR mutations also minimize aggregation and maintain the antibody’s stability and half-life by not interfering with the neonatal Fc receptor (FcRn) interactions. This advanced form of Fc engineering is crucial for creating therapeutic antibodies with reduced side effects and improved safety profiles.

Where are Fc-silenced antibodies necessary?

Fc-silenced antibodies are essential in therapeutic and research applications where activation of the immune system could be detrimental. In cancer research, for example, they allow scientists to target cancer cells without triggering immune effector functions that could harm healthy tissues. In immunotherapy, these antibodies can block specific receptors or ligands on target cells without inducing ADCC or other Fc-mediated activities. They are also valuable in in vitro assays to study antigen-antibody interactions without interference from immune cells. By eliminating unwanted effector functions, Fc-silenced antibodies reduce potential side effects and provide clearer insights into biological processes.

What determines the activity on the Fc-region?

The activity of the Fc region is determined by its ability to bind to Fc gamma receptors (FcγRs) on immune cells, which is influenced by the specific amino acid sequence and glycosylation patterns of the Fc domain. Variations in IgG subclasses (e.g., IgG1 Fc vs. IgG2 Fc) and specific residues can alter binding affinity to receptors like FcγRI and FcγRIIIA. Factors such as Fc glycosylation, aggregation, and the presence of mutations or substitutions also impact Fc-mediated effector functions like ADCC. Additionally, interactions with the neonatal Fc receptor (FcRn) affect the antibody’s half-life and pharmacokinetics. By carefully engineering these elements, we can modulate the Fc region’s activity to meet your specific therapeutic or research needs.